Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, optimal dose finding, Phase II Study of triweekly Abraxane in patients with metastatic breast cancer

Next Previous
Trial Profile

Randomized, optimal dose finding, Phase II Study of triweekly Abraxane in patients with metastatic breast cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Jan 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms ABROAD

    • Most Recent Events

    • 01 Dec 2022 Results of subgroup analysis of Randomized Phase II Study to Determine the Optimal Dose of 3-week Cycle Nab-Paclitaxel in Metastatic Breast Cancer Patients assessing influence of single nucleotide polymorphisms (SNPs) on CIPN, using genotype data published in the Acta Medica Okayama
    • 14 Dec 2019 Results assessing patient-reported outcome and health related quality of life in patients with metastatic breast cancer, presented at the 42nd Annual San Antonio Breast Cancer Symposium.
    • 17 Jul 2019 Status changed from active, no longer recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top